Accelerate to Discover

Back to filter

Related topics

Early fetal sex determination using micro-volume of maternal plasma

BJS Biotechnologies

Jun 16, 2018

 A qPCR-based assay, SneakPeek Early Gender Test (Gateway Genomics) has been developed to determine fetal sex as early...

3R Compliant drug development studies

Bruker Biospin

Jun 8, 2018

In preclinical imaging, magnetic resonance imaging (MRI) can be an attractive alternative to researchers who have...

Kinase study of cytotoxicity voted paper of the year.

Acea Biosciences

Jun 6, 2018

Society of Toxicology voted a xCELLigence based paper the Paper of the Year. The study of cytotoxicity was done using...

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Acea Biosciences

Jun 4, 2018

Search for dual action drugs against both HIV and Tuberculosis has lead to the creation of heterodimeric compounds with...

Jun 18, 2018

Mutual destruction of deep Lung tumor tissues by nanodrug‐conjugated and CQ1 imaging cytometer

Yokogawa

Jun 1, 2018

Lung cancer is a highly malignant tumor, and targeted delivery of anti‐cancer drugs to deep lung tumor tissue remains a...

Method to quantify local force distribution within biomolecular systems

LUMICKS

May 24, 2018

The journal Nano Letters has recently published the article “Quantifying Local Molecular Tension Using Intercalated DNA...

Bionano fall user workshop

BioNano Genomics

May 23, 2018

We are happy to announce the Bionano Genomics’ 2018 user workshop taking place in San Diego on October 15-16,...

Jun 18, 2018

Registering FDG/PET mouse and AMYViD/PET-CT rat studies to brain VOI atlases

Bruker Biospin

May 22, 2018

Preclinical NeuroPET is employed widely in studies of stroke, ischemia, addiction and eurodegenerative diseases. In...

Show all topics (10)

Multiplex detection of rare mutations by picoliter droplet based digital PCR

Aug 29, 2016

In cancer research, the accuracy of the technology used for biomarkers detection is remarkably
important. In this context, digital PCR represents a highly sensitive and reproducible method that could serve as an appropriate tool for tumor mutational status analysis. In particular, droplet-based digital PCR approaches have been developed for detection of tumorspecific mutated alleles within plasmatic circulating DNA. Such an approach calls for the development and validation of a very significant quantity of assays, which can be extremely costly and time consuming. Herein, we evaluated assays for the detection and quantification of various mutations occurring in three genes often misregulated in cancers: the epidermal growth factor receptor (EGFR), the v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog (KRAS) and the Tumoral protein p53 (TP53) genes. In particular, commercial competitive
allele-specific TaqMan1PCR (castPCR™) technology, as well as TaqMan1and ZEN™assays, have been evaluated for EGFR p.L858R, p.T790M, p.L861Q point mutations and in-frame deletions Del19. Specificity and sensitivity have been determined on cell lines DNA, plasmatic circulating DNA of lung cancer patients or Horizon diagnostics reference standards. To show the multiplexing capabilities of this technology, several multiplex panels for EGFR (several three- and four-plexes) have been developed, offering new"ready-to-use" tests for lung cancer patients.

Read more

Scientific paper
Product news

Get more info

Regina Fillerová

Field Application Specialist

Regina

Fillerová

+420 731 127 718

Send Message

Brand profile

RainDance Technologies

RainDance company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases.

Related products

Capable of generating more than a billion reactions in a single day, the RainDrop system surpasses all existing technologies and establishes a new performance standard in sensitivity, quantitation and multiplexing.

show detail

A fast, accurate and low-cost NGS target enrichment system that features award-winning instrumentation and pre-validated gene panels, as well as flexible open source options.

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey